These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

368 related articles for article (PubMed ID: 25660100)

  • 1. Risk factors for AIDS-defining illnesses among a population of poorly adherent people living with HIV/AIDS in Atlanta, Georgia.
    Chow JY; Alsan M; Armstrong W; del Rio C; Marconi VC
    AIDS Care; 2015; 27(7):844-8. PubMed ID: 25660100
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The changing pattern of AIDS-defining illnesses with the introduction of highly active antiretroviral therapy (HAART)in a London clinic.
    Ives NJ; Gazzard BG; Easterbrook PJ
    J Infect; 2001 Feb; 42(2):134-9. PubMed ID: 11531320
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Profile of opportunistic infections in HIV-infected patients at a tertiary care center in Lebanon.
    Naba MR; Kanafani ZA; Awar GN; Kanj SS
    J Infect Public Health; 2010; 3(3):130-3. PubMed ID: 20869674
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Opportunistic infections and other AIDS-defining illnesses in Poland in 2000-2002.
    Podlasin RB; Wiercinska-Drapalo A; Olczak A; Beniowski M; Smiatacz T; Malolepsza E; Juszczyk J; Leszczyszyn-Pynka M; Mach T; Mian M; Knysz B; Horban A
    Infection; 2006 Aug; 34(4):196-200. PubMed ID: 16896577
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Is it safe to discontinue primary Pneumocystis jiroveci pneumonia prophylaxis in patients with virologically suppressed HIV infection and a CD4 cell count <200 cells/microL?
    ; Mocroft A; Reiss P; Kirk O; Mussini C; Girardi E; Morlat P; Stephan C; De Wit S; Doerholt K; Ghosn J; Bucher HC; Lundgren JD; Chene G; Miro JM; Furrer H
    Clin Infect Dis; 2010 Sep; 51(5):611-9. PubMed ID: 20645862
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Comparison of clinical response to initial highly active antiretroviral therapy in the patients in clinical care in the United States and Brazil.
    Grinsztejn B; Veloso VG; Pilotto JH; Campos DP; Keruly JC; Moore RD
    J Acquir Immune Defic Syndr; 2007 Aug; 45(5):515-20. PubMed ID: 17558332
    [TBL] [Abstract][Full Text] [Related]  

  • 7. AIDS-defining illnesses: a comparison between before and after commencement of highly active antiretroviral therapy (HAART).
    Lian YL; Heng BS; Nissapatorn V; Lee C
    Curr HIV Res; 2007 Sep; 5(5):484-9. PubMed ID: 17896968
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Incidence of AIDS-Defining Opportunistic Infections and Mortality during Antiretroviral Therapy in a Cohort of Adult HIV-Infected Individuals in Hanoi, 2007-2014.
    Tanuma J; Lee KH; Haneuse S; Matsumoto S; Nguyen DT; Nguyen DT; Do CD; Pham TT; Nguyen KV; Oka S
    PLoS One; 2016; 11(3):e0150781. PubMed ID: 26939050
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Concordant HIV infection and visceral leishmaniasis in Ethiopia: the influence of antiretroviral treatment and other factors on outcome.
    ter Horst R; Collin SM; Ritmeijer K; Bogale A; Davidson RN
    Clin Infect Dis; 2008 Jun; 46(11):1702-9. PubMed ID: 18419422
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Determinant factors for the occurrence of tuberculosis after initiation of antiretroviral treatment among adult patients living with HIV at Dessie Referral Hospital, South Wollo, Northeast Ethiopia, 2020. A case-control study.
    Abdu M; Ali Y; Anteneh S; Yesuf M; Birhanu A; Mohamed S; Hussien A
    PLoS One; 2021; 16(3):e0248490. PubMed ID: 33724992
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Recommendations from the GESIDA/Spanish AIDS Plan regarding antiretroviral treatment in adults with human immunodeficiency virus infection (update February 2009)].
    Panel de expertos de Gesida y Plan Nacional sobre el Sida
    Enferm Infecc Microbiol Clin; 2009 Apr; 27(4):222-35. PubMed ID: 19246124
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Correlates of opportunistic infections in children infected with the human immunodeficiency virus managed before highly active antiretroviral therapy.
    Dankner WM; Lindsey JC; Levin MJ;
    Pediatr Infect Dis J; 2001 Jan; 20(1):40-8. PubMed ID: 11176565
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Changes in AIDS-defining illnesses in a London Clinic, 1987-1998.
    Mocroft A; Sabin CA; Youle M; Madge S; Tyrer M; Devereux H; Deayton J; Dykhoff A; Lipman MC; Phillips AN; Johnson MA
    J Acquir Immune Defic Syndr; 1999 Aug; 21(5):401-7. PubMed ID: 10458621
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Incidence and determinants of mortality and morbidity following early antiretroviral therapy initiation in HIV-infected adults in West Africa.
    Moh R; Danel C; Messou E; Ouassa T; Gabillard D; Anzian A; Abo Y; Salamon R; Bissagnene E; Seyler C; Eholié S; Anglaret X
    AIDS; 2007 Nov; 21(18):2483-91. PubMed ID: 18025885
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Predictors of immunological failure and determinants of suboptimal CD4 testing among adults with HIV on first-line antiretroviral therapy in Andhra Pradesh, India, 2008-2011.
    Allam RR; Murhekar MV; Bhatnagar T; Uthappa CK; Nalini C; Rewari BB; Mehendale SM
    Trans R Soc Trop Med Hyg; 2015 May; 109(5):325-33. PubMed ID: 25778736
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Effect of hepatitis C infection on progression of HIV disease and early response to initial antiretroviral therapy.
    Sullivan PS; Hanson DL; Teshale EH; Wotring LL; Brooks JT
    AIDS; 2006 May; 20(8):1171-9. PubMed ID: 16691069
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Absolute CD4 vs. CD4 percentage for predicting the risk of opportunistic illness in HIV infection.
    Gebo KA; Gallant JE; Keruly JC; Moore RD
    J Acquir Immune Defic Syndr; 2004 Aug; 36(5):1028-33. PubMed ID: 15247555
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Causes of the first AIDS-defining illness and subsequent survival before and after the advent of combined antiretroviral therapy.
    Grabar S; Lanoy E; Allavena C; Mary-Krause M; Bentata M; Fischer P; Mahamat A; Rabaud C; Costagliola D;
    HIV Med; 2008 Apr; 9(4):246-56. PubMed ID: 18366449
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Lower incidence of Pneumocystis jirovecii pneumonia among Africans in the Netherlands host or environmental factors?
    Schoffelen AF; van Lelyveld SF; Barth RE; Gras L; de Wolf F; Netea MG; Hoepelman AI;
    AIDS; 2013 Apr; 27(7):1179-84. PubMed ID: 23276810
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Pneumocystis carinii pneumonia in HIV-infected patients.
    May TA; Gruta CI; Goldschmidt RH
    Am Fam Physician; 2000 Oct; 62(8):1783, 1786. PubMed ID: 11057837
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 19.